Renji Hospital, Shanghai Jiao Tong University
Renji Hospital and the Shanghai Cancer Institute on its campus are where CARsgen's solid-tumour CAR-T work began, including the Claudin 18.2 CAR-T satri-cel for stomach cancer.
Overview
Home of the State Key Laboratory of Oncogenes and Related Genes (Shanghai Cancer Institute), where Li Zonghai developed GPC3 and Claudin 18.2 CAR-T cells before founding CARsgen; a large gastrointestinal oncology and liver programme and one of the first sites for CT041 (satricabtagene autoleucel) trials.
- Shanghai Cancer Institute
- Solid tumour CAR-T trials
- Gastrointestinal oncology
Pages like this
not linked directly; found by shared links- TrialLUMMICAR STUDY 1
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, CAR-T cell therapy and the tag china.
- InstitutionJiangsu Cancer Hospital
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
- ProductRivoceranib (apatinib)
Shares Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer and the tag china.
- ProductInaticabtagene autoleucel
Shares CAR-T cell therapy and the tag china.
- ProductSintilimab
Shares Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer and the tag china.
- PersonJia Fan
Shares Hepatocellular carcinoma and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy and the tag china.
- TrialRELIANCE
Shares CAR-T cell therapy and the tag china.